Notice of Results

Summary by AI BETAClose X

Scancell Holdings PLC will release its audited results for the year ending April 30, 2025, on Thursday, September 11, 2025, alongside a business update. A live webcast and Q&A session for analysts and investors will be hosted on the same day at 13:00 BST by the CEO and CFO. The company's lead product, iSCIB1+, has demonstrated monotherapy activity in adjuvant melanoma and showed additional clinical benefit when combined with checkpoint therapies in the Phase 2 SCOPE trial in advanced melanoma. Modi-1, the lead Moditope peptide active immunotherapy, is being investigated in a Phase 2 study in a broad range of solid tumours and has also shown encouraging interim clinical data.

Disclaimer*

UK 100

Latest directors dealings